61964-08-7

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Dihydroisobenzofuran-5-ylamine is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and potential biological activities. Its incorporation into drug molecules can enhance their therapeutic effects and target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical industry, 1,3-Dihydroisobenzofuran-5-ylamine is utilized as a precursor for the development of new agrochemicals. Its chemical properties allow for the creation of compounds with improved efficacy and selectivity in pest control and crop protection.
Used in Organic Synthesis:
1,3-Dihydroisobenzofuran-5-ylamine serves as a versatile reagent in organic synthesis, enabling the formation of a wide range of chemical compounds. Its aromatic amine structure facilitates various chemical reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Precursor for Chemical Compounds:
As a precursor, 1,3-Dihydroisobenzofuran-5-ylamine plays a crucial role in the production of other chemical compounds. Its unique structure and reactivity make it an essential component in the synthesis of various specialty chemicals, contributing to the advancement of the chemical industry.

InChI:InChI=1/C14H8N2/c15-9-13-7-6-12(8-14(13)10-16)11-4-2-1-3-5-11/h1-8H

Upstream product

• 52771-99-0 5-nitro-1,3-dihydroisobenzofuran 
• 496-14-0 1,3-dihydroisobenzofuran 

Downstream Products

• 944447-36-3 6-(2,6-dichlorophenyl)-2-[(1,3-dihydro-5-isobenzo-furanyl)amino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1391602-23-5 N-(1,3-dihydro-isobenzofuran-5-yl)-guanidine tosylate 
• 1391598-74-5 2-{2-[2-(1,3-dihydro-isobenzofuran-5-ylamino)-pyrimidin-4-yl]-pyridin-4-yl}-benzamide 
• 220513-49-5 5-bromo-1,3-dihydroisobenzofuran 

Relevant academic research and scientific papers

6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

Imidazo pyridine-2-ones and pharmaceutical compositions and methods of treatment utilizing same

1,3-Dihydroimidazo[4,5-b]pyridin-2-ones and corresponding thiones have utility as analgesic, antipyretic and antiinflammatory agents. They are generally prepared by treatment of a 2,3-diaminopyridine with phosgene or thiosphosgene followed by further substitution if desired.

Synthesis and analgesic activity of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-6]pyridin-2-ones and 3-(substituted phenyl)-1,2,3-triazolo[4,5-b]pyridines

In a study of nonsteroidal antiinflammatory and analgesic agents, a series of 1,3-dihydro-3-(substituted phenyl)imidazo[4,5-b]pyridin-2-ones and 3-(substituted phenyl)triazolo[4,5-b]pyridines was prepared. Many of the imidazolones were alkylated on the free nitrogen. In a modified Randall-Selitto analgesic assay, the pain thresholds of both the inflamed and normal foot were elevated. This is not commonly observed with nonsteroidal antiinflammatory agents. The most active compounds were 1,3-dihydro-3-[3,4-(methylenedioxy)phenyl]imidazo[4,5-b]pyridin-2-one (I-15) and its N-allyl (I-21) and N-isopropyl (I-121) derivatives. In the triazole series the 3-(2-fluoro- and 2,4-difluorophenyl)triazolo[4,5-b]pyridines (T-1 and T-8) were the best. The imidazole compounds were somewhat superior in analgesic activity to codeine and d-propoxyphene without showing any narcotic characteristics. Some of the compounds also possessed activity against carrageenan-induced foot edema in the rat, so these compounds represent a new class of nonnarcotic analgesic antiinflammatories, capable of producing a greater degree of analgesia than that obtainable with other nonsteroidal antiinflammatory agents.